Status:
RECRUITING
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Epilepsy, Temporal Lobe
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
Temporal lobe epilepsy (TLE) is a common type of epilepsy and one of the most likely to not be controlled by medication. For patients who do not respond to medication, surgery can result in a cure of ...
Detailed Description
Hippocampal sclerosis is the most common pathological finding in temporal lobe epilepsy. While CA1 and CA4 subregions are typically affected, considerable variability in the involvement of the differ...
Eligibility Criteria
Inclusion
- Healthy controls aged 18-64.
- Patients with temporal lobe epilepsy aged 18-64 and hippocampal sclerosis demonstrated on clinical MRI scan
Exclusion
- Non-English speaking participants will be excluded as we cannot provide translation services.
- Inability to provide informed consent.
- Contraindications to MRI Age \< 17 years / \>65 years
- Weight \> 127.5kg (which is the maximum weight of which a single 510mg vial of Ferumoxytol would accommodate a 4mg/kg dose).
- Women of childbearing capacity with a positive pregnancy test
- Women who are actively breast feeding
- Contraindication of Ferumoxytol -known hypersensitivity to Feraheme or any of its components -History of allergic reaction to any intravenous iron product
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06483061
Start Date
May 1 2025
End Date
September 1 2029
Last Update
May 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peter S. Allen MRI Unit
Edmonton, Alberta, Canada, T6G 2R3